ChromaDex and Walmart Launch Tru Niagen® in 3,800 Walmart Stores Across the United States
June 07 2021 - 6:33AM
Business Wire
Walmart partnership brings industry-leading NAD+ booster and
healthy aging nutrient Tru Niagen® to major U.S. retail stores for
the first time
ChromaDex Corp. (NASDAQ:CDXC) announced today the launch of its
flagship consumer product Tru Niagen® in Walmart, available in
3,800 stores across the United States. Walmart is the first major
U.S. retailer to bring this well-studied healthy aging nutrient to
stores.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20210607005115/en/
Tru Niagen® launches in 3,800 Walmart
stores (Photo: Business Wire)
“We are grateful to Walmart for their commitment to the Tru
Niagen® brand and for their collaboration in planning this launch,”
says ChromaDex CEO Rob Fried. “We are excited to make our product
available to Walmart customers.”
The industry-leading NAD+ booster will be offered to Walmart
customers in two distinct serving sizes, 100mg and 300mg. In
addition to in-store availability, both options will be available
online with same-day delivery and in-store pickup options at select
locations.
Tru Niagen® is a unique form of vitamin B3 that is clinically
proven to elevate NAD+, reducing the impact of aging and daily wear
and tear on the body. Scientifically proven superiority to
competing NAD+ precursors such as NMN (nicotinamide
mononucleotide), Niagen® is supported by a vast amount of safety
and efficacy data in humans. NAD+ is a vital coenzyme, naturally
produced in the body, and studies have shown NAD+ declines up to
50% between the ages of 40 and 60. Based on a 300mg/day serving,
Tru Niagen® can increase NAD+ by 40-50%, helping consumers Age
Better®.
Supplementation with Niagen® (patented nicotinamide riboside),
the sole active ingredient in Tru Niagen®, safely increases NAD+
levels, as demonstrated in nine published human trials. Niagen® has
achieved regulatory acceptance by the world’s four leading
regulatory bodies: the U.S. FDA, Health Canada, the European Food
Safety Authority, and the Therapeutic Goods Administration (TGA) of
Australia.
For additional information on the science supporting Tru
Niagen®, please visit www.truniagen.com.
For additional information about ChromaDex, please visit
www.chromadex.com.
For additional information on Walmart, please visit
www.walmart.com.
About ChromaDex:
ChromaDex Corp. is a global bioscience company dedicated to
healthy aging. The ChromaDex team, which includes world-renowned
scientists, is pioneering research on nicotinamide adenine
dinucleotide (NAD+), levels of which decline with age. ChromaDex is
the innovator behind NAD+ precursor nicotinamide riboside (NR),
commercialized as the flagship ingredient Niagen®. Nicotinamide
riboside and other NAD+ precursors are protected by ChromaDex’s
patent portfolio. ChromaDex delivers Niagen® as the sole active
ingredient in its consumer product Tru Niagen® available at
www.truniagen.com and through partnerships with global retailers
and distributors. ChromaDex maintains a website at
www.chromadex.com to which ChromaDex regularly posts copies of its
press releases as well as additional and financial information
about the Company.
Forward-Looking Statements:
This release contains forward-looking statements within the
meaning of Section 27A of the Securities Act of 1933, as amended,
and Section 21E of the Securities and Exchange Act of 1934, as
amended, including statements related to whether the retail
partnership will open up a new distribution channel, making Tru
Niagen® more accessible to consumers. Statements that are not a
description of historical facts constitute forward-looking
statements and may often, but not always, be identified by the use
of such words as "expects," "anticipates," "intends," "estimates,"
"plans," "potential," "possible," "probable," "believes," "seeks,"
"may," "will," "should," "could" or the negative of such terms or
other similar expressions. More detailed information about
ChromaDex and the risk factors that may affect the realization of
forward-looking statements is set forth in ChromaDex's Annual
Report on Form 10-K for the fiscal year ended December 31, 2020,
ChromaDex's Quarterly Reports on Form 10-Q and other filings
submitted by ChromaDex to the SEC, copies of which may be obtained
from the SEC's website at www.sec.gov. Readers are cautioned not to
place undue reliance on these forward-looking statements, which
speak only as of the date hereof, and actual results may differ
materially from those suggested by these forward-looking
statements. All forward-looking statements are qualified in their
entirety by this cautionary statement and ChromaDex undertakes no
obligation to revise or update this release to reflect events or
circumstances after the date hereof.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210607005115/en/
ChromaDex Media Contact: Alex Worsham, Vice President of
Global Marketing & Communications 310-388-6706 ext. 689
alexw@chromadex.com
ChromaDex Investor Relations Contact: Brianna Gerber,
Vice President of FP&A and Investor Relations 949-419-0288 ext.
127 briannag@chromadex.com
ChromaDex (NASDAQ:CDXC)
Historical Stock Chart
From Mar 2024 to Apr 2024
ChromaDex (NASDAQ:CDXC)
Historical Stock Chart
From Apr 2023 to Apr 2024